Barclays Initiates Coverage on MiniMed Group (NASDAQ:MMED)

Analysts at Barclays initiated coverage on shares of MiniMed Group (NASDAQ:MMED) in a research report issued on Wednesday,Benzinga reports. The brokerage set an “overweight” rating and a $26.00 price target on the stock. Barclays‘s target price indicates a potential upside of 81.56% from the stock’s current price.

MMED has been the topic of a number of other research reports. Wall Street Zen upgraded shares of MiniMed Group to a “hold” rating in a report on Saturday, March 14th. The Goldman Sachs Group began coverage on shares of MiniMed Group in a research report on Tuesday. They set a “buy” rating and a $24.00 price objective on the stock. Evercore began coverage on shares of MiniMed Group in a research note on Tuesday. They set an “outperform” rating and a $20.00 target price on the stock. William Blair began coverage on MiniMed Group in a report on Tuesday. They issued an “outperform” rating for the company. Finally, Citigroup began coverage on MiniMed Group in a research report on Tuesday. They issued a “buy” rating and a $23.00 target price for the company. Eleven equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, MiniMed Group presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.45.

MiniMed Group Stock Performance

NASDAQ MMED traded down $0.60 on Wednesday, hitting $14.32. 49,144 shares of the company were exchanged, compared to its average volume of 1,051,994. MiniMed Group has a twelve month low of $14.10 and a twelve month high of $20.48.

More MiniMed Group News

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Bank of America started coverage with a Buy rating and a $27 price target, flagging a pipeline-driven inflection point and implying substantial upside from current levels. MiniMed initiated with ‘Buy’ rating by Bank of America
• Positive Sentiment: Goldman Sachs, Wells Fargo, Citigroup, BTIG, Deutsche Bank, Mizuho, Evercore, Morgan Stanley and William Blair initiated coverage or issued Buy/Outperform/Overweight ratings with price targets generally in the $19–$26 range (several above $20), signaling broad institutional optimism about MiniMed’s standalone growth prospects. Zacks coverage summary
• Neutral Sentiment: Piper Sandler issued a Neutral rating with a $16 target — a more conservative view that suggests limited near-term upside relative to some peers’ forecasts. Piper Sandler initiation summary
• Neutral Sentiment: TipRanks published a note framing MiniMed as a Hold for investors balancing franchise strength versus execution risks, underscoring that upside depends on execution of the pipeline and standalone operating performance. Balancing Franchise Strength with Execution Risks

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.